You are viewing a free preview of this lesson.
Subscribe to unlock all 10 lessons in this course and every other course on LearningBro.
If stress is, at bottom, a set of physiological processes — the racing heart and surging adrenaline of the SAM pathway, the anxious arousal mediated by the brain's neurotransmitters — then one obvious way to manage it is to intervene in those processes directly, with drugs. Drug therapy is a physiological (biological) approach to stress management: rather than changing how a person thinks about a stressor, it changes the body's chemistry so that the stress response is dampened. This lesson examines the two most important classes of anti-stress drug on the AQA specification: benzodiazepines, which reduce the psychological experience of anxiety by enhancing the action of the inhibitory neurotransmitter GABA, and beta-blockers, which reduce the physical symptoms of stress — racing heart, trembling, raised blood pressure — by blocking the action of adrenaline on the heart and blood vessels. We examine how each works, how effective each is, and the serious questions of side effects and dependence that drug therapy raises. The recurring theme is a trade-off that runs through all biological treatment: drugs are fast, easy, and effective at relieving symptoms, but they treat the body's reaction rather than the source of the stress, and they carry costs of their own.
Key Definition: Drug therapy for stress uses medication to alter the biochemistry of the stress response. Benzodiazepines (BZs) reduce anxiety by enhancing the inhibitory neurotransmitter GABA, calming overall arousal of the nervous system. Beta-blockers (BBs) reduce the physical symptoms of stress by blocking the effect of adrenaline and noradrenaline on the heart and blood vessels, lowering heart rate and blood pressure.
The central insight is that the two drug classes attack stress at different points: benzodiazepines act centrally, in the brain, to reduce the feeling of anxiety, whereas beta-blockers act peripherally, on the body, to reduce the physical signs of arousal. Understanding this division is the key to understanding both their uses and their limitations.
This lesson addresses the following point in AQA A-Level Psychology (7182), Paper 3, Section C (Stress):
Assessment objectives engaged: AO1 (knowledge of how benzodiazepines and beta-blockers work to reduce stress, at the level of neurotransmitters and physiology), AO3 (evaluation of the effectiveness and appropriateness of drug therapy — speed and ease of use versus side effects, dependence, treating symptoms not causes, and comparison with psychological therapies), and — where a question includes a scenario — AO2 (recommending or evaluating a drug for a described case). This lesson is strongly synoptic with biopsychology (the nervous system and synaptic transmission) and with the biological approach.
Benzodiazepines — drugs such as diazepam (Valium) and chlordiazepoxide (Librium) — are among the most widely prescribed anti-anxiety medications. They work by enhancing the action of gamma-aminobutyric acid (GABA), the brain's principal inhibitory neurotransmitter.
To understand the mechanism, recall how synaptic transmission works (from biopsychology). Neurons communicate by releasing neurotransmitters across a synapse; some neurotransmitters are excitatory (they make the receiving neuron more likely to fire) and some are inhibitory (they make it less likely to fire). GABA is the master inhibitory neurotransmitter: when GABA binds to its receptor (the GABA-A receptor) on a receiving neuron, it opens a channel that allows negatively charged chloride ions to flow into the neuron. This makes the inside of the neuron more negative (hyperpolarised), which makes it harder for the neuron to fire. GABA is therefore the brain's natural "brake": it dampens neural activity and produces a calming effect.
Benzodiazepines do not act like GABA directly; instead, they bind to a separate site on the GABA-A receptor and enhance GABA's effect — they make the receptor respond more strongly to the GABA that is already present, allowing more chloride ions in. The result is greater inhibition of neural activity throughout the brain, which is experienced as reduced anxiety, relaxation, and sedation. By turning up the brain's natural brake, benzodiazepines reduce the over-arousal that characterises anxiety and stress.
The benzodiazepine mechanism can be summarised as a chain.
graph TD
A[Benzodiazepine taken] --> B[Binds to its own site on the GABA-A receptor]
B --> C[Enhances the effect of natural GABA at the receptor]
C --> D[Chloride channel opens more readily<br/>more chloride ions enter the neuron]
D --> E[Neuron becomes hyperpolarised<br/>harder to fire]
E --> F[Reduced neural activity across the brain]
F --> G[Lower arousal and anxiety<br/>calming, sedative effect]
Many benzodiazepines also boost the effect of serotonin, another neurotransmitter implicated in mood and anxiety, which contributes to their calming action. The overall effect is that benzodiazepines reduce the cognitive and emotional experience of stress — the worry, tension, and anxious arousal — making them useful for short-term relief of severe anxiety. Because their action is central (in the brain), they tackle the feeling of being stressed at its neurological root.
It is important to be precise about why this matters for stress. Chronic and acute stress are characterised by a state of over-arousal of the nervous system — the mind racing, the inability to switch off, the disproportionate sense of threat. In neurochemical terms, this can be understood as an imbalance in which excitatory activity outstrips the brain's inhibitory braking. By strengthening the GABA brake, benzodiazepines restore some of that balance, which is why they reduce not only subjective anxiety but also stress-related insomnia (they help an over-aroused brain to "switch off") and muscle tension. This is also why they are prescribed for acute, severe episodes — a panic-level reaction to an overwhelming stressor, for instance — where what is needed is rapid, powerful dampening of a runaway stress response. They are not, however, intended as a long-term solution, for reasons that the evaluation will make clear: the very mechanism that makes them effective (altering the GABA system) is also what makes the brain adapt to them over time.
Beta-blockers — drugs such as propranolol — work in a completely different way and on a different part of the body. Where benzodiazepines reduce the psychological experience of anxiety in the brain, beta-blockers reduce the physical symptoms of stress in the body.
Recall the sympathomedullary (SAM) pathway: when we are stressed, the sympathetic nervous system is activated and the adrenal medulla releases adrenaline (and noradrenaline) into the bloodstream. These hormones bind to beta-adrenergic receptors on the heart and blood vessels, causing the heart to beat faster and harder and the blood pressure to rise — the familiar pounding heart and tense, shaky feeling of acute stress.
Beta-blockers block these beta-adrenergic receptors. By occupying the receptor sites, they prevent adrenaline and noradrenaline from binding, so the stress hormones cannot exert their usual effect. The consequence is that:
Crucially, beta-blockers do not act on the brain to reduce the feeling of anxiety; they work peripherally, on the cardiovascular system, to reduce its physical manifestations. This is why they are used not only for cardiovascular protection but also by people who need to control the physical signs of nerves in performance situations — musicians, surgeons, and public speakers sometimes use them to steady a trembling hand or a racing heart — because the physical symptoms can be calmed even while some mental nervousness remains.
It is worth being precise about the chemistry. Adrenaline and noradrenaline are agonists at the beta-adrenergic receptor — molecules that bind to the receptor and switch it on, triggering the cardiovascular effects of stress. A beta-blocker is an antagonist: it binds to the same receptor but does not activate it, and by occupying the site it physically prevents the stress hormones from getting in. The receptor is, in effect, blocked. Because the heart's pacemaker cells are densely populated with these receptors, blocking them has a powerful slowing and steadying effect on the heartbeat. This agonist–antagonist framework (studied in Biology and Chemistry) explains the precise sense in which beta-blockers "block" stress: they do not destroy adrenaline or stop it being released — the SAM pathway still fires — they simply prevent the adrenaline that is released from reaching its target. The stress signal is sent, but the cardiovascular system no longer "hears" it.
The two drug classes are contrasted below.
| Feature | Benzodiazepines (BZs) | Beta-blockers (BBs) |
|---|---|---|
| What they target | The psychological experience of anxiety | The physical symptoms of stress |
| Where they act | Centrally, in the brain | Peripherally, on the heart and blood vessels |
| Mechanism | Enhance GABA (and serotonin), increasing neural inhibition | Block beta-adrenergic receptors, preventing adrenaline acting |
| Main effects | Reduced anxiety, relaxation, sedation | Lower heart rate and blood pressure, less trembling |
| Typical use | Short-term relief of severe anxiety | Cardiovascular protection; controlling physical nerves |
| Key risk | Dependence and tolerance | Fewer dependence problems; affects blood pressure |
A useful way to remember the division of labour is that benzodiazepines treat the mind's alarm while beta-blockers treat the body's alarm. A person taking a beta-blocker before a performance may still feel somewhat nervous, but their hands will not shake; a person taking a benzodiazepine will feel calmer but may also feel drowsy.
There is also an interesting psychological consequence of the way beta-blockers work, which connects to a recurring idea in this option. Some psychologists, drawing on the principle that we partly infer our emotional state from our bodily sensations, argue that beta-blockers may reduce anxiety indirectly as well as directly: if a person no longer feels their heart pounding and their hands trembling, they have fewer physical cues telling them "I am frightened," and so they may appraise the situation as less threatening. On this view the bodily calming produced by the beta-blocker feeds back into a calmer cognitive appraisal — a neat illustration of how the physical and psychological aspects of stress are intertwined even when the drug acts only on the body. This is one reason beta-blockers can be surprisingly helpful in performance situations: by removing the physical evidence of nerves, they can break the vicious cycle in which noticing one's own racing heart makes one feel even more anxious, which raises arousal further still.
Because the two drug classes have different onsets and risk profiles, they tend to be chosen for different purposes. Benzodiazepines are reserved for short courses in severe, acute anxiety, precisely because their dependence risk makes long-term use hazardous. Beta-blockers, with a far lower dependence risk, are more suitable where the physical component of stress needs ongoing control — for example in someone whose chronic stress is driving raised blood pressure and who therefore also gains a cardiovascular-protective benefit. Knowing which drug suits which clinical situation, and why, is exactly the kind of applied reasoning an AO2 scenario question would reward.
A major strength of drug therapy is its effectiveness in reducing the symptoms of stress, which is supported by research evidence. Benzodiazepines reliably reduce anxiety, and controlled trials comparing them with placebos generally show that they produce significantly greater symptom relief; beta-blockers demonstrably lower heart rate and blood pressure and reduce the physical signs of arousal. The implication is that drug therapy works for its intended purpose — it provides genuine, measurable relief — which makes it a valuable option, particularly for people whose stress or anxiety is so severe that they cannot function or engage with any other form of help until their arousal is brought under control.
A particular practical strength of drugs is that they are fast-acting and require very little effort from the patient, which improves accessibility and adherence. Unlike psychological therapies, which demand weeks of sessions, homework, and active cognitive effort, taking a tablet is quick, easy, and requires no special skills, motivation, or insight; benzodiazepines in particular act within hours. The implication is that drug therapy reaches people who could not, or would not, commit to a demanding psychological programme — those who are too distressed, too busy, or insufficiently motivated — and because it is undemanding, patients are often more likely to keep taking it (better adherence) than to complete a lengthy course of therapy, giving drugs a real advantage in everyday clinical practice.
Subscribe to continue reading
Get full access to this lesson and all 10 lessons in this course.